Tvardi Therapeutics, Incorporated
4 clinical trials · Sponsor
◉ Watch Tvardi Therapeutics, Incorporated
| Record | Firm | Date |
|---|---|---|
| Study of TTI-101 in Participants With Idiopathic Pulmonary Fibrosis (NCT05671835) | Tvardi Therapeutics, Incorporated | 2023-05-15 |
| A Study of TTI-101 as Monotherapy and in Combination in Participants With Locally Advanced or Metastatic, and Unresectable Hepatocellular Carcinoma (NCT05440708) | Tvardi Therapeutics, Incorporated | 2023-03-23 |
| Phase 1b/2 Study of TTI-101 in Combination for Patients With Metastatic Hormone Receptor-Positive and HER2-Negative Breast Cancer (NCT05384119) | Tvardi Therapeutics, Incorporated | 2023-01-09 |
| Oral STAT3 Inhibitor, TTI-101, in Patients With Advanced Cancers (NCT03195699) | Tvardi Therapeutics, Incorporated | 2017-11-15 |
Track Tvardi Therapeutics, Incorporated automatically
Every clearance here is in the API, with alerts when new ones post.